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Glioblastoma is the most common malignant primary brain tumor. Surgical resection, post-
operative radiotherapy plus concomitant and adjuvant chemotherapy with temozolomide
(TMZ) is the standard of care for newly diagnosed glioblastoma. In the past decade, efforts
have been made to decipher genomic and core pathway alterations to identify clinically
relevant glioblastoma subtypes. Based on these studies and more academic explorations,
new potential therapeutic targetswere found and several targeting agentswere developed.
Such molecules should hopefully overcome the resistance of glioblastoma to the current
therapy. One of the hallmarks of glioblastoma subtypes was the enrichment of extracellular
matrix/invasion-related genes. Integrins, which are cell adhesion molecules important in
glioma cell migration/invasion and angiogenesis were one of those genes. Integrins seem
to be pertinent therapeutic targets and antagonists recently reached the clinic. Although
the p53 pathway appears often altered in glioblastoma, conﬂicting results can be found
in the literature about the clinically relevant impact of the p53 status in the resistance to
TMZ. Here, we will summarize the current knowledge on (1) integrin expression, (2) p53
status, and (3) relationship between integrins and p53 to discuss their potential impact on
the resistance of glioblastoma to temozolomide.
Keywords: integrin, p53, temozolomide, glioblastoma, chemoresistance
INTRODUCTION
Glioblastoma is characterized by rapidly dividing cells, high degree
of vascularity, invasion into the normal brain tissue, and an intense
resistance to death-inducing stimuli. Signiﬁcant advances have
been made in understanding the molecular genetics underlying
the heterogeneity of glioblastoma and their resistance to thera-
pies. However, standard therapy including surgical resection and
radiotherapy with concomitant and adjuvant chemotherapy using
temozolomide (TMZ) remains poorly efﬁcient (Stupp et al., 2005).
Prognostic and predictive markers are continuously proposed
based on large scale genomic data. In the recent years, emphasis has
been given to the predictive impact of O6-methylguanine-DNA
methyltransferase (MGMT) expression/activity, a DNA repair
enzyme that protects cells against alkylating drugs such as TMZ
(Stupp et al., 2009). The promoter of the MGMT gene is methy-
lated in 40–45% of glioblastoma and the enzyme is not expressed
in the majority of these cases (Hegi et al., 2005; Silber et al., 2012).
While the contribution of MGMT toTMZ resistance is highly doc-
umented, tumors in whichMGMT is not the primary determinant
of treatment outcome also exist (Carlson et al., 2009; Combs et al.,
2011). Integrins have beenproposed toplay a role in the aggressive-
ness of gliomas andhavebeen implicated in radio/chemoresistance
in different types of tumors (Aoudjit and Vuori, 2012). The p53
protein has been largely studied in gliomas but its prognostic value
has not been consistently established. In line with our recent data
proposing an α5β1 integrin-p53 axis with potential implication
in TMZ resistance (Janouskova et al., 2012), we will summa-
rize here the current knowledge on integrins and p53 status in
glioblastoma.
INTEGRINS IN GLIOMA
BIOLOGY OF INTEGRINS
Integrins are heterodimeric cell surface receptors that mediate cell
adhesion to the extracellular matrix (ECM) and support cell–cell
interactions in a multitude of physiological and pathological sit-
uations. They are at least 24 known αβ heterodimers formed by
a combination of 18 α and 8 β subunits bound non-covalently.
Natural ligands of integrins are component of the ECM such as
vitronectin, collagen, or ﬁbronectin. Each αβ integrin pair has
a deﬁned set of ECM protein (Hynes, 2002). The repertoire of
integrins present at the membrane dictates therefore the extent
to which a cell will behave on a speciﬁc matrix and respond to
its environment. Once engaged with the ECM, integrins clus-
ter and recruit various signaling and adaptor proteins to form
focal adhesion complexes (Geiger et al., 2001). These complexes
activate intracellular downstream signaling pathways including
NF-κB, PI3K, Src, or Ras-MAP kinases (Hynes, 2002; Legate
et al., 2009). Such pathways regulate functions involved in motil-
ity, cytoskeleton organization, adhesion, proliferation, survival,
and gene transcription. Integrins link ECM to the actin cytoskele-
ton through FAK/ILK/SFK/Rho proteins pathway providing the
traction necessary for cell motility (Geiger et al., 2001). Integrins
regulate the localization and the activity of urokinase-type plas-
minogen activator (uPA)/uPA receptor (Ghosh et al., 2000; Wei
et al., 2007; Bass and Ellis, 2009) and matrix metalloproteinases
(MMPs; Lamar et al., 2008; Morozevich et al., 2009) therefore
controlling ECM remodeling and the invasive process.
Beside their mechanical functions and despite the lack of
intrinsic kinase activity, integrins are true signaling molecules.
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Integrins regulate proliferation by controlling the expression of
cyclin D1 which permits cells to enter the S-phase of the cell
cycle (Fournier et al., 2008). Integrins relay survival or apop-
totic signals depending on the surrounding environment. Integrin
ligation promote survival through various mechanisms includ-
ing increased anti-apoptotic proteins (bcl-2, FLIP; Aoudjit and
Vuori, 2001b; Matter and Ruoslahti, 2001; Uhm et al., 1999),
activation of PI3K–Akt (Aoudjit and Vuori, 2001a) or NF-κB
pathway (Scatena and Giachelli, 2002; Courter et al., 2005). Unli-
gated integrins were reported to promote apoptosis through the
so-called integrin-mediated death (IMD) a mechanism depen-
dent, or not, on caspases activation in anchorage-dependent
cells (Stupack et al., 2001; Jan et al., 2004). However, tumor
cells are often IMD-resistant and unligated integrins rather pro-
mote anchorage-independent growth, survival, and metastasis
than apoptosis (Desgrosellier et al., 2009). Additionally, cross-
talks occur between integrins, cytokines, and growth factor
receptors. Optimal growth factor stimulation relies on integrin-
mediated adhesion to an appropriate ECM protein. αvβ3/5 and
α5β1 interact with growth factor receptors (VEGFR2, c-Met,
FGFR1, PDGFR, EGFR, TIE-2, and IGF-1R) to promote full
activation of each receptor and maximal signal transduction
(increased MAPK and Akt activity) resulting in enhanced cell
migration, proliferation, survival, and angiogenesis (Friedlan-
der et al., 1995; Eliceiri, 2001; Alam et al., 2007; Soung et al.,
2010). Integrins were also reported to bind directly growth fac-
tor (such as angiopoietins or VEGF) allowing the transduction of
information in the absence of the receptor (Carlson et al., 2001;
Hutchings et al., 2003). In short, integrins sense, interpret, and
distribute information so that cancer cells adjust and respond to
their microenvironment.
INTEGRIN EXPRESSION AND FUNCTION IN GLIOMA
Clustering of transcriptomic data from high grade glioma pre-
dicted poor survival in subclasses of tumors overexpressing ECM
components such as ﬁbronectin which is the preferred ligand of
α5β1 and αvβ3 integrins (Geiger et al., 2001; Freije et al., 2004;
Bredel et al., 2005; Colin et al., 2006; Tso et al., 2006). Functional
analysis revealed gliomagenesis and glioblastoma networks com-
posed of genes that play a role in integrin signaling including
ﬁbronectin, α3 and α5 integrins (Bredel et al., 2005). Gingras
et al. (1995) investigated glioblastoma for the expression of cell
adhesion molecules including integrins that might distinguish
tumor from normal adjacent brain tissue. Results showed that
glioblastoma expressed α2, α3, α5, α6β1, and αvβ3 integrins at
signiﬁcantly higher level than normal brain tissue suggesting that
these integrins might play a role in the development or the pro-
gression of glioma (Gingras et al., 1995). β8 and α5β1 integrins
were commonly expressed in a perinecrotic or perivascular pat-
tern in glioblastoma (Riemenschneider et al., 2005). Higher levels
of α5 and β3 integrin mRNA were measured in glioblastoma
as compared to normal brain or low grade astrocytoma (Kita
et al., 2001). Average αvβ3 integrin expression in glioblastoma
seemed to exceed those in low grade glioma at the protein level
although mRNA levels of both subunits were not discrimina-
tive between glioblastoma and low grade glioma (Schnell et al.,
2008). In another study, αvβ5 and α5β1 integrins were shown
to be expressed at consistently higher levels than αvβ3 integrins
in human glioma cell explants (Mattern et al., 2005). We and
others showed recently that α5β1 integrin expression in biop-
sies from patient with glioma correlated with poor prognosis
and tumor aggressiveness (Cosset et al., 2012; Holmes et al., 2012;
Janouskova et al., 2012).
In glioma, integrins were often studied because of their cru-
cial role in tumor cell invasion (Gritsenko et al., 2012). Both β1
subunit-containing integrins (Paulus et al., 1996) and αvβ3 inte-
grins control glioma cell invasion (D’Abaco and Kaye, 2007). α2β1,
α3β1, and α5β1 integrins are overexpressed in multidrug-resistant
glioma cells and are responsible for their increased adhesive and
invasive capacities (Hikawa et al., 2000). The laminin-5 receptor
α3β1 integrin is mainly expressed in areas of tumor cell inva-
sion and support glioma cell migration and invasion (Tysnes
et al., 1996; Mahesparan et al., 2003; Kawataki et al., 2007). αvβ3
integrins promote migration and adhesion in various glioma
cells (Gladson and Cheresh, 1991; Friedlander et al., 1996) and
inhibition of αvβ3 integrin with neutralizing antibody inhibited
migration and invasion selectively in cell lines that contained a
high level of integrin expression (Wild-Bode et al., 2001). Our
laboratory extensively investigated α5β1 integrins in glioma. We
showed that α5β1 integrins increased proliferation, clonogenic
survival, adhesion, migration, and invasion of various glioma
cell lines (Maglott et al., 2006; Bartik et al., 2008; Martin et al.,
2009; Cosset et al., 2012). We also reported that the expression
of α5β1 integrins in glioma is controlled by caveolin-1 (Martin
et al., 2009; Cosset et al., 2012). Interestingly, it was shown recently
that invasive recurrent glioblastoma, resistant to antiangiogenic
therapy, overexpress α5β1 integrin and its ligand ﬁbronectin
(DeLay et al., 2012). αvβ3 integrin/ILK/RhoBpathway (Monferran
et al., 2008) and β1 integrin/AKT/p130Cas/paxillin (Cordes et al.,
2006) controlled the radiosensitivity of glioma cells by regulating
radiation-induced cell death. Recruitment of αvβ3/5 integrin in
glioblastoma cells is inducedbyhypoxia. It follows the activationof
FAK/RhoB/GSK3β pathway leading to HIF-1α induction and the
transcription of proangiogenic factors (Skuli et al., 2009). Finally,
surface expression of α6β1 integrin in U87MG cells enhanced cell
spreading and attachment on laminin-111, increased prolifera-
tion, decreased apoptosis due to serum starvation and increased
migration and invasion of U87MG cells both in vitro and in vivo
(Delamarre et al., 2009).
INTEGRINS IN GLIOMA ANGIOGENESIS
Induction of angiogenesis is essential for a tumor to grow beyond
1–2 mm and glioblastoma exhibit proliﬁc angiogenesis. Poorly
expressed in resting endothelial cells,α5β1 and αvβ3/5 integrins are
highly upregulated on endothelium cells during tumor angiogen-
esis (Bussolati et al., 2003; Avraamides et al., 2008; Desgrosellier
and Cheresh, 2010) and rapidly accessible in tumor blood vessels
(Magnussen et al., 2005). They stimulate endothelial cell prolif-
eration, promote migration, and lumen formation (Mettouchi
and Meneguzzi, 2006). Although α5β1 integrin is undoubtedly
recognized as a proangiogenic factor, controversial results for
αvβ3 integrin questioned its role (Hodivala-Dilke, 2008; Robin-
son and Hodivala-Dilke, 2011). Overexpression of αvβ3 integrin
in glioma exerted growth-suppressive effects in vivo that are linked
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to vascular defects (Reynolds et al., 2002; Kanamori et al., 2004,
2006). However, antagonists to both α5β1 and αvβ3/5 integrins are
able to inhibit tumor angiogenesis (Brooks et al., 1995; Friedlander
et al., 1995; Kim et al., 2000).
INTEGRINS IN GLIOMA STEM CELLS
Brain tumors also contain highly tumorigenic and therapeutically
resistant pluripotent stemcells referred as glioma stemor initiating
cells. The glioma stem cell hypothesis incorporates a model in
which only a small subset of cells, the glioma stem cells, can initiate
tumor. This hypothesis was conﬁrmed very recently in vivo (Lathia
et al., 2011). Elevated levels of α6β1 integrins were found in glioma
stemcells and seem to be a reliable newmarker to enrich for glioma
stem cells (Lathia et al., 2010).
Integrins are implicated at various levels of glioma develop-
ment and progression. Blocking their functions may affect both
tumoral cells and endothelial cells and these characteristics made
them attractive therapeutic targets for glioblastoma (Chamberlain
et al., 2012; Goodman and Picard, 2012). Emphasis on αvβ3 inte-
grins has been given recently as cilengitide, their prototypical small
peptide antagonist, is currently evaluated in phase III clinical trials
in glioblastoma (Tabatabai et al., 2010). Interestingly, the outcome
in a phase II trial was particularly good in patients with a methy-
lated MGMT gene promoter (Stupp et al., 2010). Emerging data
showing the role of α5β1 integrin in glioblastoma give some hope
for new therapeutic propositions in the near future.
p53 PROTEIN IN GLIOMA
p53, the “guardian of the genome,” is certainly one of the most
widely studied protein in human glioma. Activation of the tumor
suppressor p53 by stress signals triggers different cellular pro-
grams such as cell cycle arrest, apoptosis, differentiation, DNA
repair, autophagy, and senescence through complex network and
signaling pathways (Levine and Oren, 2009; Vousden and Prives,
2009; Sullivan et al., 2012). Gaining a better understanding of how
transcriptional and non-transcriptional functions of p53 integrate
will be of great importance for the proposal of new therapeutic
options (Dai and Gu, 2010; Speidel, 2010). Somatic p53 missense
mutations are found in approximately 50% of all human cancers.
Intensive research on p53 status as a classical molecular marker
led to controversial results and non-signiﬁcant clinical impact,
particularly in the glioma ﬁeld.
p53 STATUS IN GLIOMA
As most mutations in p53 gene led to the accumulation of p53 in
the nucleus, nuclear overexpression of p53 was usually considered
as amarker of mutation. Several studies showed that the expression
of p53 is correlated at 90% with its mutation (Figarella-Branger
et al., 2011). Detection of p53 mutation by the yeast functional
assay that measures quantitatively mutant p53 alleles and qualita-
tively the loss of p53 competencewas also employed and compared
to conventional techniques includingDNA sequencing (Tada et al.,
1997; Fulci et al., 2000). Overall results indicate that p53mutations
often occurred in low grade gliomas (WHO grade II astrocy-
toma; Bourne and Schiff, 2010) and thus is a frequent event in
the pathological progression of secondary glioblastoma (WHO
Grade IV;Gladson et al., 2010). Secondary glioblastoma arise from
a preexisting grade II or III astrocytoma in contrast with primary
glioblastoma that form de novo. Primary glioblastoma represent
about 90% of glioblastoma. p53 gene mutations are present in
about 30% of primary glioblastoma, and occur more frequently
in secondary glioblastoma (65%; Ohgaki et al., 2004; Zheng et al.,
2008). A recent integrated genomic analysis identiﬁed four rele-
vant subclasses of glioblastoma (proneural, mesenchymal, neural,
and classical glioblastoma). p53 mutation was observed in 54,
32, 21, and 0% of tumors from the proneural, mesenchymal,
neural, and classical glioblastoma subtype, respectively (Verhaak
et al., 2010). Interestingly, classical glioblastoma beneﬁt frommore
aggressive therapy regimen than the others (Verhaak et al., 2010).
In fact, the prognostic value of p53 status may be reconsidered
according to these data.
p53 STATUS AND GLIOBLASTOMA PROGNOSIS
No clear consensus has been reached about the prognostic value
of p53 status despite numerous studies (Table 1). A clear pic-
ture remains difﬁcult to draw due to the different techniques
used to evaluate p53 (including immunostaining on tumor tis-
sues, direct sequencing of p53 gene, and functional assays) and
the complexity of patient cohort composition. Data illustrating
an association of p53 with survival always point to a longer sur-
vival when p53 is mutated (Tada et al., 1998; Schiebe et al., 2000;
Birner et al., 2002; Burton et al., 2002). However, the majority of
studies do not validate p53 as an independent prognostic marker
for glioblastoma (Kraus et al., 2001; Simmons et al., 2001; Shiraishi
et al., 2002; Rich et al., 2005; Ruano et al., 2009; Weller et al., 2009;
Levidou et al., 2010; Rossi et al., 2011). Overall it means that the
prognostic impact of p53 aberrations is only marginal when con-
sidered in a global glioblastoma patient population. Reevaluation
of this impact in clinically relevant glioblastoma subpopulations
(see above) and association with speciﬁc molecular signatures will
certainly be of interest in the future.
p53 AND GLIOMA-INITIATING STEM CELLS
Recent studies begin to shed light onto the role of p53 in the
regulation of neural stem cells (NSCs). NSCs are self-renewing
cells in the central nervous system that can generate both neurons
and glia. An elegant study showed that dual inactivation of p53
and PTEN in murine NSC promotes an undifferentiated state with
high renewal potential and generates tumors with a high grade
glioma phenotype (Zheng et al., 2008). Although the role of p53 in
brain tumor stem cells has not been well established, data suggest
that loss of differentiation and increase in neurosphere renewal
may be linked to the disruption of the p53 pathway in glioma
(Molchadsky et al., 2010; Mendrysa et al., 2011; Spike and Wahl,
2011). To achieve a permanent eradication of brain tumors, it is
noteworthy that glioma-initiating stem cells have to be considered
and in this way their p53 status and functions need to be further
explored.
p53 AND TMZ
Despite expressingmainly awild-type p53 and thus being expected
to be sensitive to DNA-damaging agents, primary glioblastoma
resist standard therapies including chemotherapy with TMZ. This
intriguing observation is in debate and the role of p53 status
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Table 1 | Evaluation of p53 status in glioblastoma.
Evaluation of the p53 status Number of patients % of p53 mutant p53: prognostic marker? Reference
Sequencing/yeast functional assay 42 43 YES (longer survival for patients with
p53mut tumors)
Tada et al. (1998)
Sequencing 75 32 YES (longer survival for patients with
p53mut tumors)
Schiebe et al. (2000)
Sequencing/immunostaining 110 19 NO Simmons et al. (2001)
Sequencing/immunostaining 93 22 NO Kraus et al. (2001)
Sequencing/yeast functional assay 123 31 NO Shiraishi et al. (2002)
Sequencing/immunostaining 41 long-term survivors 25 YES (longer survival for patients with p53
positive tumors)
Burton et al. (2002)
48 short-term survivors 31
Immunostaining 114 / YES (longer survival for patients with p53
positive tumors)
Birner et al. (2002)
Sequencing 41 27 NO Rich et al. (2005)
Sequencing/immunostaining 194 / NO Ruano et al. (2009)
Sequencing/immunostaining 291 15 NO Weller et al. (2009)
Immunostaining 77 Meta analysis / NO Levidou et al. (2010)
Immunostaining 106 / NO Rossi et al. (2011)
in response to TMZ has been largely addressed in preclinical
studies. Conﬂicting results have been obtained (Table 2) and
show either an improved capability of TMZ to inhibit cell via-
bility when p53wt is functionally inhibited (Hirose et al., 2001; Xu
et al., 2001, 2005a,b; Dinca et al., 2008; Blough et al., 2011) or a
sensitization of cells to drugs when p53wt is functional (Hermis-
son et al., 2006; Roos et al., 2007). The former studies suggested
that glioma cells with an intact p53 gene are selectively impaired in
the proapoptotic functions of p53wt while retaining the potential
to mediate relevant DNA repair and cell cycle arrest. Treatment
with TMZ induced a persistent cell cycle arrest and an increase in
p21 (a cell cycle regulator) in functional p53-expressing cells which
showed morphological and biochemical features of senescent cells
(Hirose et al., 2001; Martinkova et al., 2010). In cells impaired for
p53 function or with a mutant p53, TMZ induced a transient cell
cycle arrest and cell death via apoptosis or mitotic catastrophe
(Hirose et al., 2001; Martinkova et al., 2010) as well as attenuation
of DNA repair (Xu et al., 2005b). When TMZ-triggered apoptosis
Table 2 | Role of p53 inTMZ outcome.
Material p53 inhibition Effect of p53 modulation onTMZ
sensibility
Reference
Glioblastoma cell lines (U87MG, LNZ308) By oncoprotein E6 Increased sensibility Hirose et al. (2001)
Glioblastoma cell lines (SWB95, SWB77, SWB33,
SWB40, SWB39, SWB61, D54) xenografts
p53-independent cell cycle arrest Bocangel et al. (2002)
Glioblastoma cell lines (U87MG, LNZ308) By piﬁthrin-α Increased sensibility Xu et al. (2005a)
Glioblastoma cell lines (D54, A172) By oncoprotein E6 Increased sensibility Xu et al. (2005b)
Glioblastoma cell lines (U87MG, U373MG, U251MG,
U138MG, LN18, LN428, LN319, LNT229, LN308,
D247MG,T98G)
By siRNA Decreased sensibility Hermisson et al. (2006)
Glioblastoma cell lines (U87MG, U138MG) By piﬁthrin-α Decreased sensibility Roos et al. (2007)
Glioblastoma cell lines (U87MG) xenografts of biopsies By piﬁthrin-α Increased sensibility Dinca et al. (2008)
Glioblastoma cell lines (U87MG, LNZ308, LN443, SF767,
U251N, U373)
Cancer stem cells
By siRNA In cell lines : increased sensibility
In stem cells : decreased sensibility
Blough et al. (2011)
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was reported for both p53wt and p53mutant cells, pathways
involved differed with activation of the FAS apoptotic pathway
or the mitochondrial apoptotic pathway, respectively (Roos et al.,
2007). Thus adverse effects of p53wt activities are increasingly rec-
ognized and may participate in chemoresistance of diverse cancers
including glioma (Kim et al., 2009; Martinez-Rivera and Siddik,
2012). In one recent report, the effect of p53 status on response
to TMZ was explored in glioma-initiating stem cells. It was shown
that tumor stem cells are resistant to TMZ when p53 is mutated
and sensitive to TMZ when intact (Blough et al., 2011). These data
add a new level of complexity in the relationship between p53
status and TMZ sensitivity in glioma.
INTEGRINS AND p53
Although p53 itself is functional in a great majority of pri-
mary glioblastoma, inactivation of the p53 signaling pathway
occurred in the form of ARF deletions, ampliﬁcations of mdm2 or
mdm4 leading to p53 signaling alterations in 87% of glioblastoma
(Network, 2008). Additionally several oncogenes such as the
glioma oncoprotein Bcl2L12 (Stegh et al., 2010) were reported
to be overexpressed in p53wt tumors and to impair p53 signal-
ing pathway. Few reports investigated the relationship between
integrins and p53 signaling pathways. Both integrin-dependent
activation (Lewis et al., 2002) and inhibition (Bao and Stromblad,
2004) of p53 signaling have been suggested in different tumoral
settings except gliomas. For example, Stromblad and colleagues
demonstrated that αvβ3 integrin impacts negatively on p53wt
activity in melanoma cells (Bao and Stromblad, 2004; Smith et al.,
2012). We proposed recently that α5β1 integrin plays a similar
role in high grade glioma (Janouskova et al., 2012). We demon-
strated that overexpression of the α5 integrin subunit in p53wt
U87MG cells impaired the activation of p53 and its transcrip-
tional activity in response to TMZ. Under such conditions, cells
became resistant to this alkylating agent. No such effects were
found in p53 mutant glioma cell lines. Interestingly, higher lev-
els of α5 integrin were found in p53wt tumor biopsies than in
p53 mutant tumor biopsies suggesting a link between this spe-
ciﬁc integrin and p53 status in vivo. Our in vitro studies also
demonstrated that SJ749 and K34c, two speciﬁc non-peptidic
antagonists of α5β1 integrin, improved the therapeutic action of
TMZ in a p53-dependent way (Martinkova et al., 2010). Molecular
pathways involved in the integrin-dependent chemoresistance in
p53wt tumors are currently unknown and deserve further stud-
ies. Proteins implicated in integrin signaling have been shown
to shuttle between the membrane and the nucleus providing a
potential mechanism for communication between integrins and
p53. In particular FAK, the main kinase activated by integrins, is
known to interfere with p53 activity in the nucleus (Lim et al.,
2008; Golubovskaya and Cance, 2011). It will also be interesting
to discriminate the potential effect of α5β1 integrin on transcrip-
tional and non-transcriptional functions of p53. Our data are the
ﬁrst to demonstrate relationships between an integrin and the
TMZ-dependent activation of p53 in glioma possibly explaining
the resistance to TMZ of a subgroup of patients. It is tempting
to suggest that inhibition of α5β1 integrin by speciﬁc antagonists
might be an adjuvant treatment to standard therapies in patients
expressing high level of α5β1 integrin and p53wt.
CONCLUSION
Despite few and sometimes conﬂicting data available both on inte-
grin expression and p53 status as prognostic and/or predictive
markers for high grade glioma, a reevaluation of their roles is
warranted. Due to the growing knowledge on glioblastoma het-
erogeneity and subclassiﬁcation, it becomes reasonable to address
these questions more accurately in well deﬁned subpopulations
of patients. Key issues need still to be addressed before proposing
α5β1 integrin expression level and p53 status as relevant biomark-
ers to stratify group of patients which may be more responsive
to TMZ.
ACKNOWLEDGMENTS
We sincerely apologize to those whose work we were unable to
discuss due to space limitations. Work in the author’s laboratory
is supported by the Ligue Contre le Cancer (Comité du Grand
Est), by Alsace contre le Cancer, by the Fondation ARC pour le
Recherche sur le Cancer. Hana Janouskova is a predoctoral fellow
from the French Ministère des Affaires Etrangères and from the
Fondation ARC pour la Recherche sur le Cancer.
REFERENCES
Alam, N., Goel, H. L., Zarif, M. J.,
Butterﬁeld, J. E., Perkins, H. M.,
Sansoucy, B. G., et al. (2007). The
integrin-growth factor receptor duet.
J. Cell. Physiol. 213, 649–653.
Aoudjit, F., and Vuori, K. (2001a).
Integrin signaling inhibits paclitaxel-
induced apoptosis in breast cancer
cells. Oncogene 20, 4995–5004.
Aoudjit, F., and Vuori, K. (2001b).
Matrix attachment regulates Fas-
induced apoptosis in endothelial
cells: a role for c-ﬂip and implications
for anoikis. J. Cell Biol. 152,
633–643.
Aoudjit, F., and Vuori, K. (2012). Inte-
grin signaling in cancer cell survival
and chemoresistance. Chemother.
Res. Pract. 2012, 283181.
Avraamides, C. J., Garmy-Susini, B.,
and Varner, J. A. (2008). Integrins in
angiogenesis and lymphangiogenesis.
Nat. Rev. Cancer 8, 604–617.
Bao,W., and Stromblad, S. (2004). Inte-
grin alphav-mediated inactivation of
p53 controls a MEK1-dependent
melanoma cell survival pathway in
three-dimensional collagen. J. Cell
Biol. 167, 745–756.
Bartik, P., Maglott, A., Entlicher, G.,
Vestweber, D., Takeda, K., Martin, S.,
et al. (2008). Detection of a hypersia-
lylated beta1 integrin endogenously
expressed in the human astrocytoma
cell line A172. Int. J. Oncol. 32,
1021–1031.
Bass, R., and Ellis, V. (2009). Regula-
tion of urokinase receptor function
and pericellular proteolysis by the
integrin alpha(5)beta(1). Thromb.
Haemost. 101, 954–962.
Birner, P., Piribauer, M., Fischer, I.,
Gatterbauer, B., Marosi, C., Ungers-
bock, K., et al. (2002). Prognostic
relevance of p53protein expression in
glioblastoma. Oncol. Rep. 9, 703–707.
Blough, M. D., Beauchamp, D. C.,West-
gate,M. R., Kelly, J. J., and Cairncross,
J. G. (2011). Effect of aberrant p53
function on temozolomide sensitivity
of glioma cell lines and brain tumor
initiating cells from glioblastoma. J.
Neurooncol. 102, 1–7.
Bocangel, D. B., Finkelstein, S., Schold,
S. C., Bhakat, K. K., Mitra, S.,
and Kokkinakis, D. M. (2002).
Multifaceted resistance of gliomas to
temozolomide. Clin. Cancer Res. 8,
2725–2734.
Bourne, T. D., and Schiff, D. (2010).
Update on molecular ﬁndings,
management and outcome in low-
grade gliomas. Nat. Rev. Neurol. 6,
695–701.
Bredel, M., Bredel, C., Juric, D.,
Harsh, G. R., Vogel, H., Recht,
L. D., et al. (2005). Functional
network analysis reveals extended
gliomagenesis pathway maps and
three novel MYC-interacting genes
in human gliomas. Cancer Res. 65,
8679–8689.
Brooks, P. C., Stromblad, S., Klemke,
R., Visscher, D., Sarkar, F. H., and
Cheresh, D. A. (1995). Antiintegrin
alpha v beta 3 blocks human breast
cancer growth and angiogenesis in
human skin. J. Clin. Invest. 96, 1815–
1822.
www.frontiersin.org October 2012 | Volume 2 | Article 157 | 5
“fonc-02-00157” — 2012/10/29 — 19:44 — page 6 — #6
Martin et al. Integrins and p53 in glioblastoma
Burton, E. C., Lamborn, K. R.,
Forsyth, P., Scott, J., O’Campo,
J., Uyehara-Lock, J., et al. (2002).
Aberrant p53, mdm2, and prolif-
eration differ in glioblastomas from
long-termcomparedwith typical sur-
vivors. Clin. Cancer Res. 8, 180–187.
Bussolati, B., Deambrosis, I., Russo,
S., Deregibus, M. C., and Camussi,
G. (2003). Altered angiogenesis and
survival in human tumor-derived
endothelial cells. FASEB J. 17, 1159–
1161.
Carlson, B. L., Grogan, P. T., Mladek,
A. C., Schroeder, M. A., Kitange,
G. J., Decker, P. A., et al. (2009).
Radiosensitizing effects of temozolo-
mide observed in vivo only in a subset
of O6-methylguanine-DNA methyl-
transferase methylated glioblastoma
multiforme xenografts. Int. J. Radiat.
Oncol. Biol. Phys. 75, 212–219.
Carlson, T. R., Feng, Y., Maisonpierre,
P. C., Mrksich, M., and Morla, A.
O. (2001). Direct cell adhesion to the
angiopoietins mediated by integrins.
J. Biol. Chem. 276, 26516–26525.
Chamberlain, M. C., Cloughsey, T.,
Reardon, D. A., and Wen, P. Y. (2012).
A novel treatment for glioblastoma:
integrin inhibition. Expert Rev. Neu-
rother. 12, 421–435.
Colin, C., Baeza, N., Bartoli, C.,
Fina, F., Eudes, N., Nanni, I., et al.
(2006). Identiﬁcation of genes dif-
ferentially expressed in glioblastoma
versus pilocytic astrocytoma using
Suppression Subtractive Hybridiza-
tion. Oncogene 25, 2818–2826.
Combs, S. E., Rieken, S., Wick, W.,
Abdollahi, A., von Deimling, A.,
Debus, J., et al. (2011). Prognostic
signiﬁcance of IDH-1 and MGMT in
patients with glioblastoma: one step
forward, and one step back? Radiat.
Oncol. 6, 115.
Cordes, N., Seidler, J., Durzok,
R., Geinitz, H., and Brakebusch,
C. (2006). beta1-integrin-mediated
signaling essentially contributes to
cell survival after radiation-induced
genotoxic injury. Oncogene 25, 1378–
1390.
Cosset, E. C., Godet, J., Entz-Werlé, N.,
Guerin, E., Guenot, D., Froelich, S.,
et al. (2012). Involvement of TGFβ
pathway in the regulation of α5β1
integrins by caveolin-1 in human
glioblastoma. Int. J. Cancer. 131,
601–611.
Courter, D. L., Lomas, L., Scatena,
M., and Giachelli, C. M. (2005). Src
kinase activity is required for integrin
alphaVbeta3-mediated activation of
nuclear factor-kappaB. J. Biol. Chem.
280, 12145–12151.
D’Abaco, G. M., and Kaye, A. H. (2007).
Integrins: molecular determinants of
glioma invasion. J. Clin. Neurosci. 14,
1041–1048.
Dai, C., and Gu, W. (2010).
p53 post-translational modiﬁcation:
deregulated in tumorigenesis. Trends
Mol. Med. 16, 528–536.
Delamarre, E., Taboubi, S., Mathieu, S.,
Berenguer, C., Rigot, V., Lissitzky, J.
C., et al. (2009). Expression of inte-
grin alpha6beta1 enhances tumorige-
nesis in glioma cells. Am. J. Pathol.
175, 844–855.
DeLay, M., Jahangiri, A., Carbonell,
W. S., Hu, Y. L., Tsao, S., Tom, M.
W., et al. (2012). Microarray analy-
sis veriﬁes two distinct phenotypes of
glioblastomas resistant to antiangio-
genic therapy. Clin. Cancer Res. 18,
2930–2942.
Desgrosellier, J. S., Barnes, L. A., Shields,
D. J., Huang, M., Lau, S. K., Pre-
vost, N., et al. (2009). An integrin
alpha(v)beta(3)-c-Src oncogenic unit
promotes anchorage-independence
and tumor progression. Nat. Med. 15,
1163–1169.
Desgrosellier, J. S., and Cheresh, D.
A. (2010). Integrins in cancer: bio-
logical implications and therapeutic
opportunities. Nat. Rev. Cancer 10,
9–22.
Dinca, E. B., Lu, K. V., Sarkaria,
J. N., Pieper, R. O., Prados,
M. D., Haas-Kogan, D. A., et al.
(2008). p53 Small-molecule inhibitor
enhances temozolomide cytotoxic
activity against intracranial glioblas-
toma xenografts. Cancer Res. 68,
10034–10039.
Eliceiri, B. P. (2001). Integrin and
growth factor receptor crosstalk. Circ.
Res. 89, 1104–1110.
Figarella-Branger, D., Maues de Paula,
A., Colin, C., and Bouvier, C.
(2011). Histomolecular classiﬁcation
of adult diffuse gliomas: the diag-
nostic value of immunohistochemi-
cal markers. Rev. Neurol. (Paris) 167,
683–690.
Fournier, A. K., Campbell, L. E.,
Castagnino, P., Liu, W. F., Chung, B.
M., Weaver, V. M., et al. (2008). Rac-
dependent cyclin D1 gene expression
regulated by cadherin- and integrin-
mediated adhesion. J. Cell Sci. 121,
226–233.
Freije, W. A., Castro-Vargas, F. E., Fang,
Z., Horvath, S., Cloughesy, T., Liau,
L. M., et al. (2004). Gene expres-
sion proﬁling of gliomas strongly
predicts survival. Cancer Res. 64,
6503–6510.
Friedlander, D. R., Zagzag, D., Shiff, B.,
Cohen,H.,Allen, J. C.,Kelly, P. J., et al.
(1996). Migration of brain tumor
cells on extracellular matrix proteins
in vitro correlates with tumor type
and grade and involves alphaV and
beta1 integrins. Cancer Res. 56, 1939–
1947.
Friedlander, M., Brooks, P. C., Shaffer,
R. W., Kincaid, C. M., Varner, J. A.,
and Cheresh, D. A. (1995). Deﬁni-
tion of two angiogenic pathways by
distinct alpha v integrins. Science 270,
1500–1502.
Fulci, G., Labuhn, M., Maier, D.,
Lachat, Y., Hausmann, O., Hegi, M.
E., et al. (2000). p53 gene muta-
tion and ink4a-arf deletion appear to
be two mutually exclusive events in
human glioblastoma. Oncogene 19,
3816–3822.
Geiger, B., Bershadsky, A., Pankov,
R., and Yamada, K. M. (2001).
Transmembrane crosstalk between
the extracellular matrix–cytoskeleton
crosstalk. Nat. Rev. Mol. Cell Biol. 2,
793–805.
Ghosh, S., Brown, R., Jones, J. C.,
Ellerbroek, S. M., and Stack, M.
S. (2000). Urinary-type plasmino-
gen activator (uPA) expression and
uPA receptor localization are regu-
lated by alpha 3beta 1 integrin in
oral keratinocytes. J. Biol. Chem. 275,
23869–23876.
Gingras, M. C., Roussel, E., Bruner, J.
M., Branch, C. D., and Moser, R.
P. (1995). Comparison of cell adhe-
sion molecule expression between
glioblastoma multiforme and autolo-
gous normal brain tissue. J. Neuroim-
munol. 57, 143–153.
Gladson, C. L., and Cheresh, D. A.
(1991). Glioblastoma expression of
vitronectin and the alpha v beta 3
integrin. Adhesion mechanism for
transformed glial cells. J. Clin. Invest.
88, 1924–1932.
Gladson, C. L., Prayson, R. A., and Liu,
W. M. (2010). The pathobiology of
glioma tumors. Annu. Rev. Pathol. 5,
33–50.
Golubovskaya, V. M., and Cance, W. G.
(2011). FAK and p53 Protein Interac-
tions. Anticancer Agents Med. Chem.
11, 617–619.
Goodman, S. L., and Picard, M.
(2012). Integrins as therapeutic
targets. Trends Pharmacol. Sci. 33,
405–412.
Gritsenko, P. G., Ilina, O., and Friedl, P.
(2012). Interstitial guidance of cancer
invasion. J. Pathol. 226, 185–199.
Hegi, M. E., Diserens, A. C., Gorlia, T.,
Hamou, M. F., de Tribolet, N.,Weller,
M., et al. (2005). MGMT gene silenc-
ing and beneﬁt from temozolomide
in glioblastoma. N. Engl. J. Med. 352,
997–1003.
Hermisson, M., Klumpp, A., Wick,
W., Wischhusen, J., Nagel, G., Roos,
W., et al. (2006). O6-methylguanine
DNA methyltransferase and p53 sta-
tus predict temozolomide sensitivity
in human malignant glioma cells. J.
Neurochem. 96, 766–776.
Hikawa, T., Mori, T., Abe, T., and
Hori, S. (2000). The ability in adhe-
sion and invasion of drug-resistant
human glioma cells. J. Exp. Clin.
Cancer Res. 19, 357–362.
Hirose, Y., Berger, M. S., and Pieper,
R. O. (2001). p53 effects both the
duration of G2/M arrest and the
fate of temozolomide-treated human
glioblastoma cells. Cancer Res. 61,
1957–1963.
Hodivala-Dilke, K. (2008). alphavbeta3
integrin and angiogenesis: a moody
integrin in a changing environment.
Curr. Opin. Cell Biol. 20, 514–519.
Holmes, K. M., Annala, M., Chua,
C. Y., Dunlap, S. M., Liu, Y.,
Hugen, N., et al. (2012). Insulin-
like growth factor-binding protein
2-driven glioma progression is pre-
vented by blocking a clinically signif-
icant integrin, integrin-linked kinase,
and NF-kappaB network. Proc. Natl.
Acad. Sci. U.S.A. 109, 3475–3480.
Hutchings, H., Ortega, N., and Plouet,
J. (2003). Extracellularmatrix-bound
vascular endothelial growth factor
promotes endothelial cell adhesion,
migration, and survival through
integrin ligation. FASEB J. 17,
1520–1522.
Hynes, R. O. (2002). Integrins: bidirec-
tional, allosteric signaling machines.
Cell 110, 673–687.
Jan, Y., Matter, M., Pai, J. T., Chen, Y. L.,
Pilch, J., Komatsu, M., et al. (2004).
A mitochondrial protein, Bit1, medi-
ates apoptosis regulated by integrins
and Groucho/TLE corepressors. Cell
116, 751–762.
Janouskova, H., Maglott, A., Leger, D.
Y., Bossert, C., Noulet, F., Guerin,
E., et al. (2012). Integrin α5β1 plays
a critical role in resistance to temo-
zolomide by interfering with the p53
pathway in high grade glioma. Cancer
Res. 72, 3463–3470.
Kanamori, M., Kawaguchi, T., Berger,
M. S., and Pieper, R. O. (2006).
Intracranial microenvironment
reveals independent opposing func-
tions of host alphaVbeta3 expression
on glioma growth and angiogen-
esis. J. Biol. Chem. 281, 37256–
37264.
Kanamori,M.,Vanden Berg, S. R., Berg-
ers, G., Berger,M. S., and Pieper, R.O.
(2004). Integrin beta3 overexpression
suppresses tumor growth in a human
model of gliomagenesis: implications
for the role of beta3 overexpression
in glioblastoma multiforme. Cancer
Res. 64, 2751–2758.
Kawataki, T., Yamane, T., Naganuma,
H., Rousselle, P., Anduren, I., Tryg-
gvason, K., et al. (2007). Laminin
Frontiers in Oncology | Radiation Oncology October 2012 | Volume 2 | Article 157 | 6
“fonc-02-00157” — 2012/10/29 — 19:44 — page 7 — #7
Martin et al. Integrins and p53 in glioblastoma
isoforms and their integrin receptors
in glioma cellmigration and invasive-
ness: evidence for a role of alpha5-
laminin(s) and alpha3beta1 integrin.
Exp. Cell Res. 313, 3819–3831.
Kim, E., Giese, A., and Deppert, W.
(2009). Wild-type p53 in cancer cells:
when a guardian turns into a black-
guard. Biochem. Pharmacol. 77, 11–
20.
Kim, S., Bell, K., Mousa, S. A., and
Varner, J. A. (2000). Regulation of
angiogenesis in vivo by ligation of
integrin alpha5beta1 with the central
cell-binding domain of ﬁbronectin.
Am. J. Pathol. 156, 1345–1362.
Kita, D., Takino, T., Nakada, M.,
Takahashi, T., Yamashita, J., and
Sato, H. (2001). Expression of
dominant-negative form of Ets-
1 suppresses ﬁbronectin-stimulated
cell adhesion and migration through
down-regulation of integrin alpha5
expression in U251 glioma cell line.
Cancer Res. 61, 7985–7991.
Kraus, J. A., Wenghoefer, M., Gles-
mann, N., Mohr, S., Beck, M.,
Schmidt, M. C., et al. (2001). TP53
gene mutations, nuclear p53 accu-
mulation, expression of Waf/p21,
Bcl-2, and CD95 (APO-1/Fas) pro-
teins are not prognostic factors in
de novo glioblastoma multiforme. J.
Neurooncol. 52, 263–272.
Lamar, J. M., Pumiglia, K. M.,
and DiPersio, C. M. (2008). An
immortalization-dependent switch
in integrin function up-regulates
MMP-9 to enhance tumor cell
invasion. Cancer Res. 68, 7371–7379.
Lathia, J. D., Gallagher, J., Heddleston, J.
M., Wang, J., Eyler, C. E., Macswords,
J., et al. (2010). Integrin alpha 6 reg-
ulates glioblastoma stem cells. Cell
Stem Cell 6, 421–432.
Lathia, J. D., Gallagher, J., Myers, J.
T., Li, M., Vasanji, A., McLendon,
R. E., et al. (2011). Direct in vivo
evidence for tumor propagation by
glioblastoma cancer stem cells. PLoS
ONE 6, e24807. doi: 10.1371/jour-
nal.pone.0024807
Legate, K. R., Wickstrom, S. A., and
Fassler, R. (2009). Genetic and
cell biological analysis of integrin
outside-in signaling. Genes Dev. 23,
397–418.
Levidou, G., El-Habr, E., Saetta, A. A.,
Bamias, C., Katsouyanni, K., Pat-
souris, E., et al. (2010). P53 immu-
noexpression as a prognostic marker
for human astrocytomas: a meta-
analysis and review of the literature.
J. Neurooncol. 100, 363–371.
Levine, A. J., and Oren, M. (2009). The
ﬁrst 30 years of p53: growing ever
more complex. Nat. Rev. Cancer 9,
749–758.
Lewis, J. M., Truong, T. N., and
Schwartz, M. A. (2002). Integrins
regulate the apoptotic response to
DNA damage through modulation of
p53. Proc. Natl. Acad. Sci. U.S.A. 99,
3627–3632.
Lim, S. T., Chen, X. L., Lim, Y.,
Hanson, D. A., Vo, T. T., Hower-
ton, K., et al. (2008). Nuclear FAK
promotes cell proliferation and sur-
vival through FERM-enhanced p53
degradation. Mol. Cell 29, 9–22.
Maglott, A., Bartik, P., Cosgun, S., Klotz,
P., Ronde, P., Fuhrmann, G., et al.
(2006). The small alpha5beta1 inte-
grin antagonist, SJ749, reduces prolif-
eration and clonogenicity of human
astrocytoma cells. Cancer Res. 66,
6002–6007.
Magnussen,A., Kasman, I. M., Norberg,
S., Baluk, P., Murray, R., and McDon-
ald, D. M. (2005). Rapid access of
antibodies to alpha5beta1 integrin
overexpressed on the luminal surface
of tumor blood vessels. Cancer Res.
65, 2712–2721.
Mahesparan, R., Read, T. A., Lund-
Johansen, M., Skaftnesmo, K. O.,
Bjerkvig, R., and Engebraaten, O.
(2003). Expression of extracellular
matrix components in a highly inﬁl-
trative in vivo glioma model. Acta
Neuropathol. 105, 49–57.
Martin, S., Cosset, E. C., Terrand,
J., Maglott, A., Takeda, K., and
Dontenwill, M. (2009). Caveolin-
1 regulates glioblastoma aggres-
siveness through the control of
alpha(5)beta(1) integrin expression
and modulates glioblastoma respon-
siveness to SJ749, an alpha(5)beta(1)
integrin antagonist. Biochim. Bio-
phys. Acta 1793, 354–367.
Martinez-Rivera, M., and Siddik, Z.
H. (2012). Resistance and gain-
of-resistance phenotypes in cancers
harboring wild-type p53. Biochem.
Pharmacol. 83, 1049–1062.
Martinkova, E., Maglott, A., Leger, D.
Y., Bonnet, D., Stiborova, M., Takeda,
K., et al. (2010). alpha5beta1 integrin
antagonists reduce chemotherapy-
induced premature senescence
and facilitate apoptosis in human
glioblastoma cells. Int. J. Cancer 127,
1240–1248.
Matter, M. L., and Ruoslahti, E.
(2001). A signaling pathway from
the alpha5beta1 and alpha(v)beta3
integrins that elevates bcl-2 tran-
scription. J. Biol. Chem. 276, 27757–
27763.
Mattern, R. H., Read, S. B., Pier-
schbacher, M. D., Sze, C. I., Eliceiri,
B. P., and Kruse, C. A. (2005). Glioma
cell integrin expression and their
interactions with integrin antago-
nists. Cancer Ther. 3A, 325–340.
Mendrysa, S. M., Ghassemifar, S., and
Malek, R. (2011). p53 in the CNS:
perspectives on development, stem
cells, and cancer. Genes Cancer 2,
431–442.
Mettouchi, A., and Meneguzzi, G.
(2006). Distinct roles of beta1 inte-
grins during angiogenesis. Eur. J. Cell
Biol. 85, 243–247.
Molchadsky, A., Rivlin, N., Brosh, R.,
Rotter, V., and Sarig, R. (2010). p53
is balancing development, differenti-
ation and de-differentiation to assure
cancer prevention. Carcinogenesis 31,
1501–1508.
Monferran, S., Skuli, N., Delmas,
C., Favre, G., Bonnet, J., Cohen-
Jonathan-Moyal, E., et al. (2008).
Alphavbeta3 and alphavbeta5 inte-
grins control glioma cell response
to ionising radiation through ILK
and RhoB. Int. J. Cancer 123,
357–364.
Morozevich, G., Kozlova, N.,
Cheglakov, I., Ushakova, N.,
and Berman, A. (2009). Integrin
alpha5beta1 controls invasion of
human breast carcinoma cells by
direct and indirect modulation of
MMP-2 collagenase activity. Cell
Cycle 8, 2219–2225.
Network, C. G. A. R. (2008). Com-
prehensive genomic characterization
deﬁnes human glioblastoma genes
and core pathways. Nature 455, 1061–
1068.
Ohgaki, H., Dessen, P., Jourde,
B., Horstmann, S., Nishikawa, T.,
Di Patre, P. L., et al. (2004).
Genetic pathways to glioblastoma: a
population-based study. Cancer Res.
64, 6892–6899.
Paulus, W., Baur, I., Beutler, A. S.,
and Reeves, S. A. (1996). Diffuse
brain invasionof glioma cells requires
beta 1 integrins. Lab. Invest. 75,
819–826.
Reynolds, L. E., Wyder, L., Lively, J. C.,
Taverna, D., Robinson, S. D., Huang,
X., et al. (2002). Enhanced pathologi-
cal angiogenesis inmice lacking beta3
integrin or beta3 and beta5 integrins.
Nat. Med. 8, 27–34.
Rich, J. N., Hans, C., Jones, B., Iversen,
E. S., McLendon, R. E., Rasheed,
B. K., et al. (2005). Gene expres-
sion proﬁling and genetic markers in
glioblastoma survival. Cancer Res. 65,
4051–4058.
Riemenschneider, M. J., Mueller, W.,
Betensky, R. A., Mohapatra, G.,
and Louis, D. N. (2005). In situ
analysis of integrin and growth fac-
tor receptor signaling pathways in
human glioblastomas suggests over-
lapping relationshipswith focal adhe-
sion kinase activation. Am. J. Pathol.
167, 1379–1387.
Robinson, S. D., and Hodivala-Dilke,
K. M. (2011). The role of beta3-
integrins in tumor angiogenesis: con-
text is everything. Curr. Opin. Cell
Biol. 23, 630–637.
Roos, W. P., Batista, L. F., Nau-
mann, S. C., Wick, W., Weller, M.,
Menck, C. F., et al. (2007). Apopto-
sis in malignant glioma cells triggered
by the temozolomide-induced DNA
lesion O6-methylguanine. Oncogene
26, 186–197.
Rossi, M., Magnoni, L., Miracco, C.,
Mori, E., Tosi, P., Pirtoli, L., et al.
(2011). beta-catenin and Gli1 are
prognostic markers in glioblastoma.
Cancer Biol. Ther. 11, 753–761.
Ruano, Y., Ribalta, T., de Lope, A.
R., Campos-Martin, Y., Fiano, C.,
Perez-Magan, E., et al. (2009). Worse
outcome in primary glioblastoma
multiforme with concurrent epider-
mal growth factor receptor and p53
alteration. Am. J. Clin. Pathol. 131,
257–263.
Scatena, M., and Giachelli, C. (2002).
The alpha(v)beta3 integrin, NF-
kappaB, osteoprotegerin endothelial
cell survival pathway. Potential role
in angiogenesis. Trends Cardiovasc.
Med. 12, 83–88.
Schiebe, M., Ohneseit, P., Hoffmann,
W., Meyermann, R., Rodemann, H.
P., and Bamberg, M. (2000). Analy-
sis of mdm2 and p53 gene alterations
in glioblastomas and its correlation
with clinical factors. J. Neurooncol.
49, 197–203.
Schnell, O., Krebs, B., Wagner, E.,
Romagna, A., Beer, A. J., Grau, S.
J., et al. (2008). Expression of inte-
grin alphavbeta3 in gliomas corre-
lates with tumor grade and is not
restricted to tumor vasculature. Brain
Pathol. 18, 378–386.
Shiraishi, S., Tada, K., Nakamura, H.,
Makino, K., Kochi, M., Saya, H.,
et al. (2002). Inﬂuence of p53 muta-
tions on prognosis of patients with
glioblastoma. Cancer 95, 249–257.
Silber, J. R., Bobola, M. S., Blank,
A., and Chamberlain, M. C.
(2012). O(6)-Methylguanine-DNA
methyltransferase in glioma therapy:
promise and problems. Biochim. Bio-
phys. Acta 1826, 71–82.
Simmons, M. L., Lamborn, K. R., Taka-
hashi, M., Chen, P., Israel, M. A.,
Berger, M. S., et al. (2001). Analy-
sis of complex relationships between
age, p53, epidermal growth factor
receptor, and survival in glioblastoma
patients. Cancer Res. 61, 1122–1128.
Skuli, N., Monferran, S., Del-
mas, C., Favre, G., Bonnet,
J., Toulas, C., et al. (2009).
Alphavbeta3/alphavbeta5 integrins-
FAK-RhoB: a novel pathway for
www.frontiersin.org October 2012 | Volume 2 | Article 157 | 7
“fonc-02-00157” — 2012/10/29 — 19:44 — page 8 — #8
Martin et al. Integrins and p53 in glioblastoma
hypoxia regulation in glioblastoma.
Cancer Res. 69, 3308–3316.
Smith, S. D., Enge, M., Bao, W., Thull-
berg, M., Costa, T. D., Olofsson,
H., et al. (2012). Protein Kinase C
alpha (PKCalpha) regulates p53 local-
isation and melanoma cell survival
downstreamof integrin alphav in 3D-
collagen and in vivo. J. Biol. Chem.
287, 29336–29347.
Soung, Y. H., Clifford, J. L., and Chung,
J. (2010). Crosstalk between integrin
and receptor tyrosine kinase signal-
ing in breast carcinoma progression.
BMB Rep. 43, 311–318.
Speidel, D. (2010). Transcription-
independent p53 apoptosis: an alter-
native route to death. Trends Cell Biol.
20, 14–24.
Spike, B. T., and Wahl, G. M. (2011).
p53, stem cells, and reprogramming:
tumor suppression beyond guarding
the genome. Genes Cancer 2, 404–
419.
Stegh, A. H., Brennan, C., Mahoney,
J. A., Forloney, K. L., Jenq, H. T.,
Luciano, J. P., et al. (2010). Glioma
oncoprotein Bcl2L12 inhibits the p53
tumor suppressor. Genes Dev. 24,
2194–2204.
Stupack, D. G., Puente, X. S.,
Boutsaboualoy, S., Storgard, C. M.,
and Cheresh, D. A. (2001). Apopto-
sis of adherent cells by recruitment
of caspase-8 to unligated integrins. J.
Cell Biol. 155, 459–470.
Stupp, R., Hegi, M. E., Mason, W. P.,
van den Bent, M. J., Taphoorn, M. J.,
Janzer, R. C., et al. (2009). Effects of
radiotherapy with concomitant and
adjuvant temozolomide versus radio-
therapy alone on survival in glioblas-
toma in a randomised phase III study:
5-year analysis of the EORTC-NCIC
trial. Lancet Oncol. 10, 459–466.
Stupp, R., Hegi, M. E., Neyns, B., Gold-
brunner, R., Schlegel, U., Clement,
P. M., et al. (2010). Phase I/IIa study
of cilengitide and temozolomidewith
concomitant radiotherapy followed
by cilengitide and temozolomide
maintenance therapy in patients with
newly diagnosed glioblastoma. J.
Clin. Oncol. 28, 2712–2718.
Stupp, R., Mason, W. P., van den Bent,
M. J.,Weller,M., Fisher, B., Taphoorn,
M. J., et al. (2005). Radiotherapy plus
concomitant and adjuvant temozolo-
mide for glioblastoma. N. Engl. J.
Med. 352, 987–996.
Sullivan, K. D., Gallant-Behm, C. L.,
Henry, R. E., Fraikin, J. L., and
Espinosa, J. M. (2012). The p53 cir-
cuit board. Biochim. Biophys. Acta
1825, 229–244.
Tabatabai, G., Weller, M., Nabors, B.,
Picard, M., Reardon, D., Mikkelsen,
T., et al. (2010). Targeting integrins
in malignant glioma. Target Oncol. 5,
175–181.
Tada, M., Iggo, R. D., Waridel, F.,
Nozaki, M., Matsumoto, R., Sawa-
mura, Y., et al. (1997). Reappraisal of
p53 mutations in human malignant
astrocytic neoplasms by p53 func-
tional assay: comparison with con-
ventional structural analyses. Mol.
Carcinog. 18, 171–176.
Tada, M., Matsumoto, R., Iggo, R. D.,
Onimaru, R., Shirato, H., Sawamura,
Y., et al. (1998). Selective sensitivity
to radiation of cerebral glioblastomas
harboring p53mutations. CancerRes.
58, 1793–1797.
Tso, C. L., Freije, W. A., Day, A.,
Chen, Z., Merriman, B., Perlina, A.,
et al. (2006). Distinct transcription
proﬁles of primary and secondary
glioblastoma subgroups. Cancer Res.
66, 159–167.
Tysnes, B. B., Larsen, L. F., Ness,
G. O., Mahesparan, R., Edvardsen,
K., Garcia-Cabrera, I., et al. (1996).
Stimulation of glioma-cell migration
by laminin and inhibition by anti-
alpha3 and anti-beta1 integrin anti-
bodies. Int. J. Cancer 67, 777–784.
Uhm, J. H., Dooley, N. P., Kyritsis, A.
P., Rao, J. S., and Gladson, C. L.
(1999). Vitronectin, a glioma-derived
extracellular matrix protein, protects
tumor cells from apoptotic death.
Clin. Cancer Res. 5, 1587–1594.
Verhaak, R. G., Hoadley, K. A., Purdom,
E., Wang, V., Qi, Y., Wilkerson, M.
D., et al. (2010). Integrated genomic
analysis identiﬁes clinically relevant
subtypes of glioblastoma character-
ized by abnormalities in PDGFRA,
IDH1, EGFR, and NF1. Cancer Cell
17, 98–110.
Vousden, K. H., and Prives, C. (2009).
Blinded by the light: the growing
complexity of p53. Cell 137, 413–431.
Wei, Y., Tang, C. H., Kim, Y., Robil-
lard, L., Zhang, F., Kugler, M. C.,
et al. (2007). Urokinase receptors are
required for alpha 5 beta 1 integrin-
mediated signaling in tumor cells. J.
Biol. Chem. 282, 3929–3939.
Weller, M., Felsberg, J., Hartmann, C.,
Berger, H., Steinbach, J. P., Schramm,
J., et al. (2009). Molecular predic-
tors of progression-free and overall
survival in patients with newly diag-
nosed glioblastoma: a prospective
translational study of the German
Glioma Network. J. Clin. Oncol. 27,
5743–5750.
Wild-Bode, C.,Weller,M., andWick,W.
(2001). Molecular determinants of
glioma cell migration and invasion.
J. Neurosurg. 94, 978–984.
Xu, G. W., Mymryk, J. S., and Cairn-
cross, J. G. (2005a). Inactivation
of p53 sensitizes astrocytic glioma
cells to BCNU and temozolomide,
but not cisplatin. J. Neurooncol. 74,
141–149.
Xu, G. W., Mymryk, J. S., and
Cairncross, J. G. (2005b).
Pharmaceutical-mediated inactiva-
tion of p53 sensitizes U87MG glioma
cells to BCNU and temozolomide.
Int. J. Cancer 116, 187–192.
Xu, G. W., Nutt, C. L., Zlatescu, M. C.,
Keeney, M., Chin-Yee, I., and Cairn-
cross, J. G. (2001). Inactivation of p53
sensitizes U87MG glioma cells to 1,
3-bis(2-chloroethyl)-1-nitrosourea.
Cancer Res. 61, 4155–4159.
Zheng, H., Ying, H., Yan, H.,
Kimmelman, A. C., Hiller, D. J.,
Chen, A. J., et al. (2008). p53
and Pten control neural and glioma
stem/progenitor cell renewal and dif-
ferentiation. Nature 455, 1129–1133.
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or ﬁnancial relationships that
could be construed as a potential con-
ﬂict of interest.
Received: 06 September 2012; paper
pending published: 18 September 2012;
accepted: 16 October 2012; published
online: 31 October 2012.
Citation: Martin S, Janouskova H and
Dontenwill M (2012) Integrins and p53
pathways in glioblastoma resistance to
temozolomide. Front. Oncol. 2:157. doi:
10.3389/fonc.2012.00157
This article was submitted to Frontiers
in Radiation Oncology, a specialty of
Frontiers in Oncology.
Copyright © 2012 Martin, Janouskova
and Dontenwill. This is an open-access
article distributed under the terms of the
Creative Commons Attribution License,
which permits use, distribution and
reproduction in other forums, provided
the original authors and source are cred-
ited and subject to any copyright notices
concerning any third-party graphics etc.
Frontiers in Oncology | Radiation Oncology October 2012 | Volume 2 | Article 157 | 8
